Citicoline: Better Evidence in Stroke Recovery Than in Healthy Brains

← Back to articles

Citicoline (CDP-choline) is a naturally-occurring intermediate in phosphatidylcholine synthesis. It is licensed as a prescription drug (Somazina, Ceraxon) in Europe, Japan, and Latin America for stroke recovery and vascular cognitive impairment. In the US it is sold as a dietary supplement with broader claims that outrun the evidence.

Stroke recovery

The ICTUS trial (n=2,298) randomised acute ischaemic stroke patients to citicoline 2,000 mg/day or placebo for 6 weeks. The primary composite endpoint at 90 days — recovery on the modified Rankin Scale, NIHSS, and Barthel Index — was not significantly different between groups (Davalos 2012; PMID 22691567; DOI 10.1016/S0140-6736(12)60813-7). After ICTUS, European stroke guidelines downgraded routine use; some pre-ICTUS meta-analyses had reported a small benefit in selected subgroups, but the trial weight has shifted against generalised use in acute stroke.

Vascular cognitive impairment

The IDEALE study and other trials have evaluated long-term oral citicoline (500–1,000 mg/day, often 9–12 months) in vascular cognitive impairment after stroke or due to small-vessel disease. Pooled effects are small but consistent for the MMSE and other cognitive scales (Alvarez-Sabin 2011, Stroke; Gareri 2015 review in Clinical Interventions in Aging). Effect sizes are modest and the safety profile is unusually clean.

Cognition in healthy adults

Smaller trials in healthy adults have produced mixed results on attention and memory. The most consistent positive signal is on sustained-attention tasks; memory benefits in non-impaired adults are inconsistent. Citicoline supports phospholipid synthesis and cholinergic tone; it doesn't add capacity to a healthy brain in the way it appears to support a damaged one.

Dose and form

Typical supplement dose is 250–500 mg/day. Pharmaceutical doses for stroke and cognitive decline are 1,000–2,000 mg/day. Cognizin (a branded citicoline used in multiple trials) is the formulation with the most consistent label-accuracy testing. "CDP-choline" and "citicoline" name the same molecule.

Safety

Tolerability is excellent — mild GI upset is the most common complaint. There are no major drug-interaction signals. Citicoline can lower blood pressure modestly; use caution stacking with antihypertensives. Pregnancy data are limited.